AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (296.3 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees

Laura Cortesi1 ( ), Federica Domati2, Annalisa Guida2, Isabella Marchi1, Angela Toss2, Elena Barbieri1, Luigi Marcheselli2, Marta Venturelli2, Simonetta Piana3, Claudia Cirilli4, Massimo Federico2
Department of Oncology and Hematology, University Hospital of Modena, Modena 41124, Italy
Department of Medical and Surgical Sciences for Children & Adults, Division of Medical Oncology, University Hospital of Modena, Modena 41124, Italy
Pathology Unit, Azienda USL Reggio Emilia, IRCCS, Reggio Emilia 42123, Italy
Modena Cancer Registry, Public Health Department, AUSL Modena 41126, Italy
Show Author Information

Abstract

Objective

As prostate cancer (PrC) shows a BRCA mutation rate as high as 30%, it becomes crucial to find the optimal selection criteria for genetic testing. The primary objective of this study was to evaluate the BRCA mutation rate in families with PrC associated with breast and/or ovarian cancers; secondary aims were to compare the characteristics of families and BRCA-related PrC outcome among BRCA1 and BRCA2 carriers.

Methods

Following the Modena criteria for the BRCA test, we evaluated the mutation rate in families with breast and/or ovarian cancer with a Gleason score ≥7 PrCs, by testing breast or ovarian cases and inferring the mutation in the prostate cases. The characteristics of families and BRCA-related PrC outcomes were measured using the chi-square (χ2) test and Kaplan–Meier methods, respectively.

Results

Among 6,591 families, 580 (8.8%) with a Gleason score ≥ 7 PrCs were identified, of which 332 (57.2%) met the Modena selection criteria for BRCA testing. Overall, 215 breast or ovarian cancer probands (64.8%) were tested, of which 41 resulted positive for BRCA and one for CHEK2 genes (19.5%). No statistically significant differences were found in BRCA-related PrC prognosis and in the characteristics of families among BRCA1, BRCA2 and non-tested patients. Ten of 23 (44%) mutations in the BRCA2 gene fell in the prostate cancer cluster region (PCCR) at the 3′ terminal of the 7914 codon.

Conclusions

It appears the Modena criteria are very useful for BRCA testing selection in families with breast and/or ovarian cancer and PrC. A trend toward a worse prognosis has been found in BRCA2 carriers.

Keywords

breast cancerovarian cancerprostate cancerhereditary cancerBRCA genesModena criteria

References

1

Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019; 10: 63-89.
Crossref Google Scholar
2

Gori S, Dieci MV, Biganzoli L, Calabrese M, Cortesi L, Criscitiello C, et al. Linee Guida AIOM Neoplasie della Mammella. Milano: Intermedia. 2019.
3

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424.
Crossref Google Scholar
4

Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl. 2012; 14: 409-14.
Crossref Google Scholar
5
PDQ® Cancer Genetics Editorial Board. PDQ Genetics of Prostate Cancer. Bethesda, MD: National Cancer Institute. Updated 11/12/2020. Available at: https://www.cancer.gov/types/prostate/hp/prostate-genetics-pdq. [PMID: 26389227].
6

Song WH, Kim SH, Joung JY, Park WS, Seo HK, Chung J, et al. Prostate cancer in a patient with a family history of BRCA mutation: a case report and literature review. J Korean Med Sci. 2017; 32: 377-81.
Crossref Google Scholar
7

Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72: 1117-30.
Crossref Google Scholar
8

Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002; 94: 1365-72.
Crossref Google Scholar
9

Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999; 91: 1310-6.
Crossref Google Scholar
10

Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. The Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998; 62: 676-89.
Crossref Google Scholar
11
Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [Updated 2016 Dec 15]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1247/.
12

Federico M, Maiorana A, Mangone L, Turchetti D, Canossi B, Cortesi L, et al. Identification of families with hereditary breast and ovarian cancer for clinical and mammographic surveillance: The Modena Study Group proposal. Breast Cancer Res Treat. 1999; 55: 213-21.
Crossref Google Scholar
13

Cortesi L, Turchetti D, Marchi I, Fracca A, Canossi B, Rachele B, et al. Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience. BMC Cancer. 2006; 6: 210.
Crossref Google Scholar
14

Cortesi L, Baldassarri B, Ferretti S, Razzaboni E, Bella M, Bucchi L, et al. A regional population-based hereditary breast cancer screening tool in Italy: first 5-year results. Cancer Med. 2020; 9: 2579-89.
Crossref Google Scholar
15

Artusi V, Chiesi L, Bernardis I, Tenedini E, Artuso L, Cavallini GM, et al. A next generation sequencing amplicon-based strategy to explore inherited retinal degeneration complexity. Eur J Hum Gen. 2015; 23: 78.
Google Scholar
16

Tenedini E, Artuso L, Bernardis I, Artusi V, Percesepe A, De Rosa L, et al. J. Amplicon-based next-generation sequencing: an effective approach for the molecular diagnosis of epidermolysis bullosa. Br J Dermatol. 2015; 173: 731-8.
Crossref Google Scholar
17

Spurdle AB, Healey S, Devereau A, Hogervorst FBL, Monteiro ANA, Nathanson KL, et al. ENIGMA – evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat. 2012; 33: 2-7.
Crossref Google Scholar
18

Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, et al. Nordic Twin Study of Cancer (NorTwinCan) Collaboration. Familial risk and heritability of cancer among twins in Nordic countries. JAMA. 2016; 315: 68-76.
Crossref Google Scholar
19

Kote-Jarai Z, Mikropoulos C, Leongamornlert DA, Dadaev T, Tymrakiewicz M, Saunders EJ, et al. UK Genetic Prostate Cancer Study Collaborators, and ProtecT Study Group. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. Ann Oncol. 2015; 26: 756-61.
Crossref Google Scholar
20

Westerman ME, Gershman B, Karnes RJ, Thompson RH, Rangel L, Boorjian SA. Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy. World J Urol. 2015; 34: 1115-22.
Crossref Google Scholar
21

Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, et al. Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol. 2019; 76: 831-42.
Crossref Google Scholar
22
National Collaborating Centre for Cancer (UK). Familial Breast Cancer: Classification and Care of People at Risk of Familial Breast Cancer and Management of Breast Cancer and Related Risks in People with a Family History of Breast Cancer. Cardiff (UK): National Collaborating Centre for Cancer (UK). 2013. Last updated: 20/11/2019.
23

Rantapero T, Wahlfors T, Kähler A, Hultman C, Lindberg J, Tammela TL, et al. Inherited DNA repair gene mutations in men with lethal prostate cancer. Genes (Basel). 2020; 11: 314.
Crossref Google Scholar
24

Jakubowska A, Nej K, Huzarski T, Scott RJ, Lubiński J. BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer. 2002; 87: 888-91.
Crossref Google Scholar
25

Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed. 2005; 7: 60.
Google Scholar
26

Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer. 2008; 99: 371-4.
Crossref Google Scholar
27

Patel VL, Busch EL, Friebel TM, Cronin A, Leslie G, McGuffog L, et al. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness. Cancer Res. 2020; 80: 624-38.
Crossref Google Scholar
Cancer Biology & Medicine
Volume 18 Issue 2,
May 2021
Pages 470-476
DOI: 10.20892/j.issn.2095-3941.2020.0481
Cite this article:
Cortesi L, Domati F, Guida A, et al. BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees. Cancer Biology & Medicine, 2021, 18(2): 470-476. https://doi.org/10.20892/j.issn.2095-3941.2020.0481

62

Views

0

Downloads

3

Crossref

4

Web of Science

4

Scopus

Altmetrics
Published: 01 May 2021
©2021 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License
Return